Drug Profile
Research programme: smart growth factor based therapies - Silver Creek
Alternative Names: SGF-1; SGF-2; SGF-3Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Silver Creek Pharmaceuticals
- Class Anti-ischaemics; Heart failure therapies; Ischaemic heart disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries; Diabetic nephropathies; Focal segmental glomerulosclerosis; Heart failure; Kidney disorders; Myocardial infarction; Tissue degeneration
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Brain injuries in USA
- 28 Feb 2022 No recent reports of development identified for preclinical development in Diabetic-nephropathies in USA
- 28 Feb 2022 No recent reports of development identified for preclinical development in Focal-segmental-glomerulosclerosis in USA